Your browser doesn't support javascript.
loading
Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study.
Velin, M; Dugourd, P-M; Sanchez, A; Bahadoran, P; Montaudié, H; Passeron, T.
Afiliação
  • Velin M; Dermatology Department, Université Côte d'Azur, CHU Nice, Nice, France.
  • Dugourd PM; Dermatology Department, Université Côte d'Azur, CHU Nice, Nice, France.
  • Sanchez A; Dermatology Department, Université Côte d'Azur, CHU Nice, Nice, France.
  • Bahadoran P; Dermatology Department, Université Côte d'Azur, CHU Nice, Nice, France.
  • Montaudié H; Dermatology Department, Université Côte d'Azur, CHU Nice, Nice, France.
  • Passeron T; INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.
J Eur Acad Dermatol Venereol ; 36(7): e539-e542, 2022 07.
Article em En | MEDLINE | ID: mdl-35143077
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Penfigoide Bolhoso / Omalizumab Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Penfigoide Bolhoso / Omalizumab Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article